CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.

ABSTRACT:

Introduction

Prostate cancer is a highly heterogeneous disease, with remarkably different prognosis across all stages. Increased circulating tumor cell (CTC) count (≥ 5) using the CellSearch assay has been identified as one of the markers that can be used to predict survival, with added value beyond currently available prognostic factors. Recently, androgen receptor splice variant 7 (AR-V7) detection has been associated with worse outcomes for patients with castration-resistant prostate cancer (CRPC) treated with novel androgen receptor-signaling (ARS) inhibitors such as abiraterone and enzalutamide but not taxane chemotherapies. Areas covered: In this manuscript, the authors review the available biomarkers in CRPC and discuss emerging data on the value of CTC-derived AR-V7 status

SUBMITTER: Bastos DA 

PROVIDER: S-EPMC6088794 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature